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LETTERS TO THE EDITOR 919product was 8?8% of the dose. A recent paper by Aswania
et al. (5), which used urinary output, calculated the
percentage of the inhaled dose delivered to the lung at
between 2 and 3%. In view of the disparity between these
three sets of figures, it may still be necessary to carry out
controlled clinical trials with each new inhaled product in
order to determine clinical ecacy and bioequivalence. The
use of in vitro particle size estimation may be suitable for
quality control purposes as long as it is recognized that it
does not reflect lung deposition or distribution or implied
bioavailability.
A. M. EDWARDS
University Medicine, Southampton General Hospital,
Southampton, U.K.
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Sir,
Response to letter from
Dr A. M. Edwards in assessing
lung deposition of
inhaled medications.
(Respir Med 1999; 93: 123–133)shows the diculty in pulling together key points from a
variety of inputs at a workshop. It is clear from numerous
publications that lung deposition from breath-actuated dry-
powder inhalers increases with increasing inspiratory flow
rate, in contra-distinction to the situation with metered
dose inhalers.
We entirely agree that in vitro measurements of aerosol
fine particle fraction are not reliably predictive of lung
deposition, and we made the point that their principal value
was in quality control. The data Dr Edwards quotes
support our statement that ‘The FPF (fine particle fraction)
measured by in vitro methods generally overestimates the
lung deposition measured using in vivo systems’. The
disparity between the two in vivo measurements he quotes
(radiolabelled lung deposition and urinary output) is
dicult to evaluate since they were not made in the same
subjects under the same conditions. Bioequivalence could
be established (in theory) by comparing radiolabelled lung
deposition of two dierent products, or urinary excretion of
two dierent products, but not by comparing radiolabelled
deposition of one with urinary output of another; whereas
the ‘gold standard’ for comparing clinical ecacy is to
carry out a clinical trial.
Our consensus statement was intended to summarize the
current state-of-the-art and clarify the value and correct use
of the various methods of estimating lung deposition of
inhaled medications, and to review the potential for new or
improved methods to increase the accuracy of these
estimations, with the possibility that eventually surrogate
in vivo methods might be able to replace some of the clinical
testing required today.
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Dear Editor
Bovine TB alertWe thank Dr Edwards for his interest in our consensus
statement. He is correct in his comment; the reference we
quoted was not appropriate to the point being made, andKoch’s discovery of the tubercle bacillus in 1882, and of
‘Old Tuberculin’ soon afterwards, paved the way for cattle
TB control schemes by test and slaughter or reactors. His
mistaken view that bovine TB was not a risk to man, at
least led to exhaustive studies of TB. Bang pioneered such
work in Denmark and noted in 1892 [cited in Francis (1) ]:
It is found that the tuberculin test is no more perfect
than are other things in this world. Sometimes it fails.
Animals with a very real degree of tuberculosis will
sometimes fail to react, and the same applies to animals
with a very slight degree of the disease. Further, a
positive reaction has been observed several times in
animals in which no tuberculous changes were found on# 2000 HARCOURT PUBLISHERS LTD
